As the school season approaches, let's ensure the children with #UCD and schools are ready. #UreaCycleDisorder #RareDisease Check #NUCDF for an Educator Guide to UCD -> bit.ly/4cK2afO

Zevra today announced that an U.S. FDA Advisory Committee meeting to review the New Drug Application for #arimoclomol as a first-in-class treatment for #NiemannPick Disease Type C will take place on August 2. #NPC #FDA #AdComm $ZVRA More details at bit.ly/3S155sV

Zevra is attending #SERGG 2024 conference, July 11-13. Our medical team will present a poster highlighting expanded access real-world data of #arimoclomol in adults with #NPC. $ZVRA More about the meeting: bit.ly/3zvHGcB

Our Sr. Director, U.S. Medical Affairs and Patient Advocacy, Tara Greene, is presenting at the #NNPDF Family Support and Medical Conference in Salt Lake City, Utah. Don’t miss Tara’s "Corporate Update," this Saturday, July 13, at 11:00 a.m. MT. NNPDF $ZVRA

Our team had a rewarding experience at the #NNPDF Family Support and Medical Conference engaging with #NPC families and advocates. We thank everyone for organizing and participating in this important event, and we look forward to next year!

Joshua Schafer, our Chief Commercial Officer and Executive Vice President of Business Development, shared his journey to joining Zevra Therapeutics with Angela Gabriel of BioSpace. Read about Josh’s career evolution and resounding commitment to patients: bit.ly/3SgCnUN $ZVRA

The school season is just around the corner! For children with #UCD, it's important to feel prepared to manage their diet at school. Encourage them to understand their food choices and how to stay healthy throughout the day. #UreaCycleDisorder #RareDisease

$ZVRA to share second quarter financial results and business updates on Tuesday, August 13, and will host a webcast at 4:30 p.m. ET. For registration details, see the release: bit.ly/3A8L51q

Today, the U.S. FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted favorably that the data support #arimoclomol as effective treatment for patients with #NiemannPick disease type C. Read the full release here: bit.ly/3WyJc5H $ZVRA

Zevra looks forward to presenting at the Canaccord Genuity (Canaccord Genuity) 44th Annual Growth Conference on August 14. For registration and more information, follow the link: bit.ly/3YCsZPy $ZVRA

#UreaCycleDisorders (UCDs), caused by deficiencies in the enzymes or transporters of the urea cycle, can cause elevated ammonia levels in the body and potential brain damage. Early diagnosis and treatment are key to managing #UCDs. Learn more: bit.ly/4frIQ9r

Zevra announces financial results and corporate updates for the second quarter 2024. See full release and webcast details at bit.ly/4djCqYp $ZVRA #InvestorRelations

#WorldNarcolepsyDay is September 22! Zevra supports Project Sleep in raising #awareness about how people living with #narcolepsy can manage their chronic illness. Learn more about this individualized process: bit.ly/45NYNl6

#ICYMI: Our Chief Medical Officer, Adrian Quartel, MD, FFPM, discussed our Phase 2 results of #KP1077 for treating #IdiopathicHypersomnia with Chelsie Derman of HCPLive. Check it out: bit.ly/3Ytfa5C $ZVRA

Zevra will participate in upcoming investor conferences, including the H.C. Wainwright & Co. 26th Annual Global Investment Conference and the Cantor Fitzgerald 2024 Global Healthcare Conference. More information here: bit.ly/4dEYEEp $ZVRA #CantorHCC #InvestorRelations

Zevra is a proud sponsor of the International Network for Fatty Acid Oxidation Research and Management (INFORM) 2024 Symposium September 1-2, in Porto, Portugal. Find more details on the event here: bit.ly/3TbGH8f $ZVRA #NiemannPick #NPC

Zevra is pleased to present new clinical data on #arimoclomol for #NiemannPick disease type C and pharmacokinetic modeling of #OLPRUVA for #UreaCycleDisorders at @ssiem2024_porto. More details on the conference: bit.ly/3XsAKGw $ZVRA #NPC #UCDs #SSIEM2024

We value our continued partnership with the #NiemannPick community and ongoing efforts to positively impact the lives of individuals affected by #NPC. We're proud to collaborate with the Firefly Fund and the NPC community to highlight the urgent need for an FDA approved therapy.

Zevra presented 4 posters of clinical results demonstrating #arimoclomol's safety and efficacy in #NiemannPick disease type C and a poster highlighting pharmacokinetic modeling of nitrogen scavengers and #OLPRUVA in #UreaCycleDisorders: bit.ly/47j0d8A $ZVRA #SSIEM2024

#NiemannPick disease type C (#NPC) is an ultra-rare, genetic, progressive and fatal neurological disease that occurs in chidlren and adults. Patients experience disease progression in speech, swallow, cognition, fine motor and mobility. Learn more: bit.ly/4dRucHd